BioVersys AG

BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company founded in 2008. It focuses on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. The company's award-winning TRIC technology has the potential to overcome resistance mechanisms, block virulence production, and directly affect the pathogenesis of harmful bacteria, offering new treatment options in the antimicrobial and microbiome fields.

With a slogan of "Leadership in overcoming the antibiotic resistance crisis," BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Its most advanced research and development programmes include addressing nosocomial infections of Acinetobacter baumannii (BV100, Phase 2) and tuberculosis (BVL-GSK098, Phase 2) in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille.

BioVersys, headquartered in Switzerland and located in the TechPark in the thriving biotech hub of Basel, received a significant Fr.12.30M Series C investment on 07 May 2024 from GlaxoSmithKline. This investment showcases the confidence of a major player in the pharmaceutical industry in BioVersys' potential to make a meaningful impact in overcoming the antibiotic resistance crisis.